Inhibikase Therapeutics (NYSE:IKT – Get Free Report) and SQZ Biotechnologies (NYSE:SQZ – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Volatility & Risk
Inhibikase Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.
Valuation and Earnings
This table compares Inhibikase Therapeutics and SQZ Biotechnologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | N/A | N/A | -$19.03 million | ($0.39) | -4.36 |
| SQZ Biotechnologies | $18.16 million | 0.04 | -$79.46 million | ($2.61) | -0.01 |
Inhibikase Therapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Inhibikase Therapeutics and SQZ Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | N/A | -350.63% | -201.82% |
| SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Inhibikase Therapeutics and SQZ Biotechnologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| SQZ Biotechnologies | 0 | 0 | 0 | 0 | 0.00 |
Inhibikase Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 252.94%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Inhibikase Therapeutics is more favorable than SQZ Biotechnologies.
Summary
SQZ Biotechnologies beats Inhibikase Therapeutics on 7 of the 13 factors compared between the two stocks.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
